Compare Ascendis Pharma A/S (ASND) vs Teradyne, Inc. (TER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Teradyne, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Teradyne, Inc. trades at $349 (market cap $56.29B). The key difference: Teradyne, Inc. is far larger — about 3.2× Ascendis Pharma A/S's market cap, and Teradyne, Inc. pays a 0.14% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TER | |
|---|---|---|
Market Cap | $17.74B | $56.29B |
Sector | Health | Technology |
52-Week High | $277.18 | $483.84 |
52-Week Low | $163.32 | $90.15 |
Enterprise Value | $18.11B | $56.13B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Teradyne (TER) trades at $359.60, down 0.87% amid a bearish technical signal, though it remains supported by strong fundamentals including a 22.55% net income margin and consistent earnings beats. Recent news highlights AI-driven data center demand boosting revenue, with Q2 2026 EPS expected at $2.04. The company maintains robust profitability metrics like 28.75% ROE, but faces headwinds from negative net cash flow trends and elevated valuation ratios (P/E 66.72).
Outlook: TER's AI and robotics exposure offers growth potential, with a consensus price target of $453.60 implying 26% upside. Risks include semiconductor cycle volatility and high valuations. Analyst sentiment is bullish (64.5% buy ratings), but investors should monitor execution on Q2 earnings and cash flow improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
